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Abstract
Background: While there is increasing evidence on the association between cannabis use and psychotic outcomes,
it is still unclear whether this also applies to depression. We aim to assess whether risk of depression and other
affective outcomes is increased among cannabis users.
Methods: A cohort study of 45 087 Swedish men with data on cannabis use at ages 18–20. Diagnoses of unipolar
disorder, bipolar disorder, affective psychosis and schizoaffective disorder were identified from inpatient care
records over a 35-year follow-up period. Cox proportional hazard modeling was used to assess the hazard ratio (HR)
of developing these disorders in relation to cannabis exposure.
Results: Only subjects with the highest level of cannabis use had an increased crude hazard ratio for depression
(HR 1.5, 95% confidence interval (CI), 1.0-2.2), but the association disappeared after adjustment for confounders.
There was a strong graded association between cannabis use and schizoaffective disorder, even after control for
confounders, although the numbers were small (HR 7.4, 95% CI, 1.0-54.3).
Conclusion: We did not find evidence for an increased risk of depression among those who used cannabis. Our
finding of an increased risk of schizoaffective disorder is consistent with previous findings on the relation between
cannabis use and psychosis.
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Background
While there is increasing evidence on the association be-
tween cannabis use and psychotic outcomes [1], it is still
unclear whether this also applies to other psychiatric dis-
orders, especially depression. Several clinical studies and
case reports have found an association between cannabis
use and subsequent depression, but the causal direction of
the association has been difficult to establish [2-4].
A review by Degenhardt et al. [5] found a modest associ-
ation between heavy or problematic cannabis use and de-
pression, but little evidence for an association between
depression and infrequent cannabis use [5]. A review by
Moore et al. [6] identified ten cohort studies that exam-
ined diagnoses of depression, of which five reported evi-
dence of an association with cannabis use that persisted
after adjustment for confounding. However, two of these
five studies found significant associations only in sub-
group analyses, while the range of potentially important
confounders adjusted for in the majority of the studies
was rather limited. Moreover, only four of the ten cohort
studies excluded participants with affective symptoms at
baseline. Similarly inconsistent findings were reported in a
multinational study by de Graaf et al. [7], which reported a
modest overall association between cannabis use and later
risk of depression, but also showed that the nature of the
association is not consistent between countries.
Degenhardt et al. [5] and Moore et al. [6] concluded that
findings on the association between cannabis and depres-
sion were inconsistent, probably due to small samples and
problems related to reverse causality. The inconsistency of
findings across the different studies may also be due to the
use of different measures of cannabis use as well as
affective outcomes [8] and inadequate consideration of
confounding [6]. Risk factors for depression include ex-
posure to adverse life events, presence of other mental
health problems, socio-economic adversity, substance use
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and problematic peer relationships [9,10]. Since these fac-
tors are also associated with cannabis use [5,6,11], control
for these is important.
Psychotic symptoms are present not only in schizo-
phrenia, but also in affective psychoses and bipolar dis-
orders. The evidence that cannabis use increases the risk
of psychotic symptoms implies that there may also be
associations between cannabis and affective disorders
with psychotic features, such as schizoaffective and bipo-
lar disorders. Moreover, epidemiological and genetic mo-
lecular studies have found evidence that schizophrenia
and bipolar disorder share some common genetic causes
[12,13]. There may also be other risk factors in common
across these disorders, such as cannabis use. Therefore,
while the diagnosis of schizoaffective disorder is contro-
versial [14], we find it of interest to assess whether can-
nabis consumption might increase its occurrence.
Another specific outcome of interest is manic or hypo-
manic episodes, for which an association with cannabis
use has been found [15].
Different mechanisms have been proposed to explain a
possible association between cannabis use and depression.
In animal experiments, long-term exposure to cannabi-
noids has been found to alter the activity of 5-HT sero-
tonin receptors [16]. There is strong evidence that
disruptions to the serotonin system at least partly underlie
the pathophysiological mechanisms that lead to depres-
sion [16]. It has been suggested that large doses of delta-9-
tetrahydrocannabinol, the main psychoactive component
of cannabis, can, in the longer-term, result in depression
through the effects of THC on serotonin and other neuro-
transmitters [5]. However, as yet, there is no animal model
to support this hypothesis. Long-term heavy cannabis use
has also been associated with significant bilateral reduc-
tion in hippocampal and amygdala volumes [17]. Given
the association between depression and hippocampal vol-
ume reduction [18], it is feasible that depressive symptoms
occur as a consequence of structural brain changes follow-
ing long-term cannabis use.
It has also been hypothesized that heavy cannabis use
may precipitate depression indirectly by reducing edu-
cational attainment, earning capacity and quality of so-
cial relationships through its effects on cognition and
motivation [5].
The Swedish conscript survey is, to date, the largest
population-based cohort study with data on cannabis
use, and also on a number of social and personality
background factors. The conscript cohort has been used
previously to examine the association between cannabis
and schizophrenia [19,20], and cannabis and suicide
[21]. The aim of the present study was to address the as-
sociation between cannabis and depression. Although
depression is a common condition, diagnostic data was
available from inpatient care only, and it was therefore
not possible to examine associations across the whole
spectrum of depressive disorders. Accordingly, we focus
here on depressive states severe enough to warrant hos-
pital admission. Our specific aims were to examine:
– whether there is an increased risk of depression
among cannabis users compared with non-users;
– whether any such association differs according to
the affective outcome in question;
– whether there is an association between cannabis
and schizoaffective disorder
Methods
Study population
The data used in this study were derived from a nation-
wide survey of 50 087 Swedish men, who were examined
for compulsory military training in 1969–1970. Con-
scription examination was compulsory for all young
Swedish men until recently. However, this cohort is the
only one that has retained personal identification on
matters related to drug use and other behavioral charac-
teristics, thereby enabling record linkage with Sweden’s
National Inpatient Register. Over 98% of the men were
aged 18–20 years at conscription, and only 2–3% of
them were exempted from conscription, mainly due to a
severe mental or physical handicap or a congenital dis-
order. The conscription procedure took 1½ days for each
subject to complete. All were given an IQ test and
responded to two questionnaires. The first questionnaire
concerned social background, upbringing conditions,
friendship, relationships, attitudes, and adjustment at
school and work. The second concerned use of alcohol,
tobacco and other substances. In addition, all the con-
scripts underwent a medical examination, and also a
structured interview with a psychologist. The ones who
reported or presented psychiatric problems were re-
ferred to a psychiatrist, and any psychiatric disorders
found was diagnosed according to the International
Classification of Diseases (8th revision).
A total of 607 subjects with depression (ICD-8; 3004)
and 30 with psychosis (ICD-8; 295, 296, 297, 298) were
identified during conscription, and they were therefore
excluded from the analysis. In order to avoid misclassifi-
cation of outcome, 11 subjects who had diagnoses of
both depression and either schizoaffective disorder or
schizophrenia during follow-up were also excluded. Due
to missing information on cannabis use, we excluded a
further 3 614 individuals. The final analytical sample
consisted of 45 087 subjects, born 1949–51.
Permission to use the conscription database for re-
search purposes and to perform the relevant record lin-
kages was granted by the Stockholm Regional Ethical
Review Board.
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Exposure
Information on use of cannabis and other drugs was
obtained from the conscription questionnaire on alcohol,
tobacco and substance use. The questions covered whether
subjects had ever used drugs, which drugs had been used
from a list of alternatives, the first drug used, the drug most
commonly used, and how many times a drug had been used.
The main cannabis measure that we employed was
reported level of cannabis use as categorized in the re-
sponse options in the questionnaire: Never, Once, 2–4, 5–
10, 11–50, >50. However, due to the small numbers of
cases in the sub-groups analyses, we compared outcomes
for those having ever used cannabis (thus collapsing all
subjects who reported cannabis use into one category)
with those who had never used cannabis, and also com-
pared outcomes for those reporting highest level of use
(‘>50 times’) with those who had never used cannabis.
Outcomes and follow-up
The Swedish National Inpatient Register, which records
all inpatient admissions to hospitals in Sweden, was used
to identify admissions for selected diagnoses from 1973
until 2007. The Swedish register recorded approximately
83% of all psychiatric admissions in 1973, 97% in 1974–
1983, and 95% in 1984–1986, and has been virtually
complete since 1987. Diagnoses were coded according to
the Swedish version of the ICD (ICD-8 during 1965–
1986, ICD-9 1987–1996, ICD-10 1997–2007), and
divided into the following diagnostic groups: 1. Unipolar
depression, 2. Bipolar disorder and affective psychosis, 3.
Schizoaffective disorder.
Unipolar depression:
– ICD 8: Depressive neurosis (300.40)
– ICD 9: Depressive disorder not elsewhere classified
(311), neurotic depression (300E)
– ICD 10: Depressive episode (F32) excluding 323, and
recurrent depressive disorder (F33) excluding 333
Bipolar disorder and affective psychosis:
– ICD 8:
 Affective psychosis consisting of involutional
melancholia (296.00)
 Manic-depression psychosis consisting of manic type
(296.10), depressed type (296,20), circular type
(296.30), other (296.88) and unspecified (296.99)
– ICD 9:
 Unipolar affective psychosis consisting of manic or
hypomanic episodes (296A), melancholia (296B)
 Bipolar affective psychosis consisting of manic type
(296 C), melancholia type (296D), mixed form
(296E), other (296 W) and unspecified (296X)
– ICD 10:
 Manic episode (F30), bipolar affective disorder (F31),
severe depressive episode with psychotic symptoms
(F323), and recurrent depressive disorder with
current psychotic symptoms (F333)
Schizoaffective disorder:
– ICD 8: Schizophrenia, type schizoaffective (295.0)
– ICD 9: Schizoaffective form (295 H)
– ICD 10: Schizoaffective disorders (F25).
Furthermore, we conducted a specific analysis for the
diagnoses of mania, which included the following diag-
nostic codes:
– ICD 8: Manic-depressive psychosis (296.10).
– ICD 9: Bipolar affective psychosis, manic type
(296 C).
– ICD 10: Manic episode (F30, F31.0, F31.1, F31.2)
Data were linked to Sweden’s National Cause of
Death Register and the Swedish Migration Register.
About 1 300 individuals emigrated from Sweden, and
2 620 died during the follow-up period. The date of first
emigration and day of death were used as censoring
points. First diagnoses of any of the outcomes above were
used as the primary end-points. The mean follow-up
period from conscription to censoring of data was
32 years, with a range of 1 day to 35 years.
Possible confounders
We selected potential confounding variables on the basis
of prior research indicating that they are likely to be
associated with both cannabis use and affective out-
comes. Relevant variables were obtained from the con-
scription questionnaires and psychological assessments.
a) Diagnosis of personality disorders assessed by a
psychiatrist at conscription: any vs. none.
b) IQ score consisted of four main subtests parts
(verbal IQ, visuospatial ability, general knowledge
and mechanical ability); these four subtests were
aggregated to give an overall standardized
intelligence score, ranging 1 to 9 (< 74, 74 to 81, 82
to 89, 90 to 95, 96 to 104, 105 to 110, 111 to 118,
119 to 126, > 126). The IQ test has been described
elsewhere in detail [22,23].We further transformed
the standard-nine values into a composite standard-
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three scale: highest (111 to > 126) vs. middle (90 to
110), lowest (< 74 to 89).
c) The variable “Disturbed behavior in childhood” was
derived from questions on truancy from school
(once a week, once a month, once per term,
occasionally), having been in contacts with police
and childcare authorities (once, more, never),
running away from home (once, more, never), and
having been sanctioned in school (once, more,
never). These four questions were aggregated to give
an overall standardized composite score ranging
from 0–9: very low (0 to 1) vs. low (2 to 3), average
(4 to 5), high (6 to 7), very high (8 to 9).
d) The variable “Social adjustment” was derived from
questions on popularity at school (1 = very popular
to 5 = unpopular), number of close friends (> 5 to
none), being in a relationship with a girl (more than
a year, several months, one month or less, no).
These three questions were aggregated to give an
overall standardized score ranges from 0–11: very
good (0 to 2) vs. good (3 to 5), low (6 to 8), very low
(9 to 11).
e) The variable “Risky use of alcohol” was derived from
questions on high consumption of alcohol: none vs.
at least one of the following indicators–
consumption of at least 250 g 100% alcohol/week;
have taken an eye-opener during a hangover; have
been apprehended for drunkenness; have reported
being drunk often.
f ) The variable “Smoking” was based on self-reported
information from questionnaires: 1= >20 cigarettes/
day; 2 = 11–20 cigarettes/day; 3 = 1–10 cigarettes/
day; 4 = non-smokers.
g) “Early adulthood socioeconomic position (Early
adulthood SEP)” was based on information from
Statistics Sweden on occupation: 1) high/
intermediate nonmanual 2) low nonmanual 3)
manual skill/unskilled 4) farmers/self-employed/
unclassified.
h) “Use of other drugs” (Mebumal, Opium, Preludin,
Morphine) was based on information from
questionnaires: any vs. none.
i) “Brought up in a city” was based on self-reported
information on upbringing: Rural vs. city with less
than 50 000 inhabitants, city with more than 50 000
inhabitants, any one of Sweden’s three large
metropolitan areas (Stockholm, Gothenburg, and
Malmö).
Statistical analyses
First, the overall depression was defined as first hospital
admission for any diagnosis of unipolar depression, bipo-
lar disorder or affective psychosis. Second, specific ana-
lyses were performed for unipolar depression, and
bipolar disorder and affective psychosis. Due to variation
in the ICD coding system over the years, we placed both
bipolar disorder and affective psychosis in the same cat-
egory. Third, an analysis was performed on the associ-
ation between cannabis use and schizoaffective disorder.
Fourth, we performed a specific analysis of the associ-
ation between cannabis use and manic disorder.
Cox proportional hazard modeling was used to assess
the relative risks of developing the outcomes in relation
to cannabis exposure. We explored the effect of each in-
dividual confounder on the relationship between canna-
bis use and each outcome. Crude and adjusted hazard
ratio (HR), with 95% confidence interval (CI), was com-
puted by level of cannabis use, and also for each poten-
tial confounder. We assessed the proportional hazard
assumption between cannabis use and each outcome by
using a Kaplan-Meier plot. We tested the equality across
strata of each individual confounder to explore whether
or not to include them in the final model. For the cat-
egorical variables we used the log-rank test of equality
across strata; in fact, all the variables listed as possible
confounders were retained. The quality of the model
was tested by running a logistic regression and calculat-
ing Hosmer-Lemeshow’s GOF test which had a value
Table 1 Hazard ratios for overall depression by reported frequency of cannabis use
Cannabis use No. exposed No. cases HR Crude HR adjusted*
Never 39 978 990 1 1
Once 1 202 28 0.9 (0.6-1.4) 0.9 (0.6-1.5)
2–4 1 486 51 1.4 (1.1-1.9) 1.2 (0.8-1.8)
5–10 839 24 1.2 (0.7-1.8) 1.1 (0.6-1.8)
11–50 727 24 1.3 (0.8-1.9) 0.6 (0.3-1.2)
>50 855 29 1.5 (1.0-2.2) 0.8 (0.4-1.5)
TOTAL 45 087 1 146
* Adjustments for: prior personality disorders at conscription, IQ, disturbed behavior in childhood, social adjustment, risky use of alcohol, smoking, early adulthood
socioeconomic position, use of other drugs, brought up in a city.
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was 0.55, showing that our observed results match the
expected of the model population. The analyses were
performed in SAS 9.1 for Windows.
Results
Among the 45 087 subjects, a total of 1 146 individuals
had depression (2.5%) during the 35 years of follow-up,
and about 14% had used cannabis by age 18 to 20.
Table 1 shows hazard ratios for depression (any case of
unipolar disorder, bipolar disorder, or affective psych-
osis) by level of reported cannabis use. No association
was found between frequency of cannabis use and risk
of depression. Only subjects with the highest level of
cannabis use had an increased crude hazard ratio for de-
pression, but this association disappeared after adjust-
ment for the confounders. Individual adjustment for
each confounder showed that the variable that most
contributed to reducing the hazard ratio was the com-
posite variable ‘disturbed behavior in childhood’, which
reduced the hazard ratio to one (data not shown).
Table 2 shows the hazard ratios for the two outcomes
unipolar disorder and bipolar disorder/affective psychosis,
by category of cannabis use. The heaviest cannabis use
(>50 times) was associated with an increased risk of uni-
polar depression (HR 1.8, 95% CI, 1.2-2.7), but this associ-
ation was eliminated by adjustment for confounding.
Disturbed behavior in childhood was again the confounder
that most attenuated the hazard ratios (data not shown).
Table 3 shows the hazard ratios for schizoaffective dis-
order by levels of cannabis use. There was a strong
graded association between cannabis use and schizoaf-
fective disorder. Even after control for confounding,
there was a more than six-fold increased hazard ratio for
subjects with the highest consumption level of cannabis
(>50 times) in comparison with those who had never
used cannabis.
A total of 118 cases of mania were identified in the full
sample. Eight cases were found among subjects who had
used cannabis (all levels of use), and one case among
those with the highest consumption level. The hazard
ratio for manic disorder of those who had used cannabis,
compared with non-users, was 0.96 (95% CI, 0.4-1.9).
Table 4 shows the contribution of the different confoun-
ders to the outcome depression, crude and adjusted. Dis-
turbed behavior was the variable most strongly associated
with later depression, even after control for other variables
(HR 2.7, 95% CI, 1.3-5.4). Also IQ, social adjustment and
prior personality disorder were strong predictors.
Discussion
Our main finding was that, after control for confounding
factors and especially markers of disturbed behavior dur-
ing childhood, there was no increased risk of future de-
pression among cannabis users at age 18 to 20. With the
large number of cases, and control for important back-
ground factors, we believe our study adds to previous
findings supporting the hypothesis that cannabis use
does not increase the risk of depression [24-26].
Cannabis use has also been associated with suicide
[27]. However another study using the same longitudinal
population as our study, found no association between
cannabis and subsequent risk of completed suicide after
adjusting for confounders [21]. Given the strong associ-
ation between severe depression and suicide, our find-
ings are consistent with those of Price et al. [21].
Table 2 Associations between cannabis use and affective outcomes
No. exposed No. cases HR Crude HR adjusted*
BIPOLAR DISORDER/AFFECTIVE PSYCHOSIS
Never used cannabis 39 978 335 1 1
Ever used cannabis 5 109 45 1.1 (0.7-1.4) 1.1 (0.7-1.7)
>50 times 855 5 0.8 (0.3-1.8) 0.3 (0.1-2.2)
UNIPOLAR DISORDER
Never used cannabis 39 978 655 1 1
Ever used cannabis 5 109 111 1.3 (1.1-1.6) 1.0 (0.7-1.2)
>50 times 855 24 1.8 (1.2-2.7) 0.9 (0.5-1.6)
* Adjustments for: prior personality disorders at conscription, IQ, disturbed behavior in childhood, social adjustment, risky use of alcohol, smoking, early adulthood
socioeconomic position, use of other drugs, brought up in a city. The category “Ever used cannabis” includes all individuals who reported cannabis use, including
those who reported “>50 times”.
Table 3 Association between cannabis use and
schizoaffective disorder
SCHIZOAFFECTIVE No.
exposed
No.
cases
HR
Crude
HR
adjusted*
Never used
cannabis
39 978 47 1 1
Ever used
cannabis
5 109 12 2.1 (1.1-3.8) 0.8 (0.2-2.9)
>50 times 855 7 7.5 (3.4-16.7) 7.4 (1.0-54.3)
* Adjustments for: prior personality disorders at conscription, IQ, disturbed
behavior in childhood, social adjustment, risky use of alcohol, smoking, early
adulthood socioeconomic position, use of other drugs, brought up in a city.
The category “Ever used cannabis” includes all individuals who reported
cannabis use, including those who reported “>50 times”.
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In contrast to a previous study [15], we did not find
any increased risk of manic disorder associated with can-
nabis use. However the number of cases was small and
particular caution is needed in drawing any conclusions
from this result.
We found a strong association between history of can-
nabis use and schizoaffective disorder, which persisted
after adjusting for confounders. Other studies have not
been able to assess the effect of cannabis specifically on
schizoaffective disorder, but have examined a broader
spectrum of schizophrenia spectrum disorders [6]. The
finding of a substantially increased risk of schizoaffective
disorder among cannabis users is consistent with previ-
ous findings on the associations between cannabis and
different schizophrenia-related disorders [6,28].
Limitations
Identification of diagnoses of depression was limited to
inpatient care, which means that our findings may not
be applicable to milder forms of depression that do not
require inpatient care. The diagnosis schizoaffective dis-
order has questionable validity as a separate clinical en-
tity [14], but is often made when psychotic features are
prominent, so we found it important to analyze separ-
ately. In this category, we only included those subjects
with a diagnosis of schizoaffective disorder who did not
also have a diagnosis of depression or schizophrenia dur-
ing follow-up, to minimize overlapping diagnoses.
Regarding the validity of diagnoses in Sweden’s National
Inpatient Register, several studies have demonstrated ad-
equate validity of major psychiatric diagnoses for epi-
demiological studies [29,30]. Information about cannabis
use was restricted to data on the use of drugs by indivi-
duals up to time of conscription. However, consumption
generally declines with age [31], so it is unlikely that the
consumption pattern would change over time to the ex-
tent that potentially bias the association between canna-
bis use and depression. Although misreporting of
information on drug use, the validity of the questions in
the conscript surveys have been assessed previously and
found to be satisfactory [32,33]. Further, we investigated
the number of hospital admissions with a diagnosis of
drug abuse during the follow-up period, and found a
high correlation between level of cannabis use at con-
scription and hospital admission for drug abuse.
Conclusions
We did not find evidence for an increased risk of de-
pression among subjects with history of cannabis use by
age 18 to 20. Our finding that there is an increased risk
of schizoaffective disorder related to cannabis use is con-
sistent with previous studies of cannabis and psychosis.
Our results indicate that the association between can-
nabis use and subsequent severe depression is likely to
be confounded by common risk factors for both, such as
disturbed behavior during childhood. More research is
needed to explore if there is any association between
cannabis use and milder forms of depression. However,
given the lack of association with severe depression
whereas a strong relationship with schizoaffective dis-
order was found suggests that cannabis use may mainly
be associated with psychotic disorders.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All the authors contributed to the conception and design of the study,
analysis and interpretation of the data, and drafting the paper and revising it
critically for key intellectual content. Finally, they all approved the final
version.
Acknowledgements
Our work was supported by a grant from the Swedish Council for Working
Life and Social Research (project no. 2009–1611). We acknowledge the
valuable comments and suggestions of Sofia Löfving, Susanne Wicks and
Johan Söderlund.
Table 4 Risk of depression by potential confounders
POTENTIAL CONFOUNDERS HR Crude Analysis HR adjusted for other potential confounders*
Prior personality disorders (any vs. none)a 2.6 (2.0-3.4) 1.8 (1.2-2.5)
IQ score (lowest vs. highest)1 2.9 (2.4-3.4) 2.2 (1.7-2.8)
Risky use of alcohol indicators (none vs. at least one)b 1.7 (1.5-2.0) 1.1 (0.9-1.4)
Smoking (>20 cigarettes/day vs. non-smokers)2 2.6 (2.0-3.3) 1.7 (1.2-2.4)
Disturbed behavior in childhood (very high vs. very low)3 3.8 (2.1-6.8) 2.7 (1.3-5.4)
Social adjustment (very low vs. very good)4 2.2 (1.3-3.6) 2.0 (1.0-3.9)
Early adulthood SEP (manual skill/unskilled vs. high/intermediate nonmanual)5 1.6 (1.3-2.0) 1.2 (1.0-1.5)
Use of other drugs (any vs. none)c 0.8 (0.3-2.3) 0.6 (0.2-2.6)
Brought up in a city (metropolitan areas vs. rural)6 0.9 (0.8-1.1) 0.8 (0.6-1.1)
* adjusted for all potential confounders and cannabis use.
a, b, c dichotomous variable.
1, 2, 3, 4, 5, 6 categorical variables, only one exposure group presented in the table.
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